Mechanisms of DNA-Specific Autoimmunity in Systemic Lupus Erythematosus
系统性红斑狼疮 DNA 特异性自身免疫机制
基本信息
- 批准号:10374852
- 负责人:
- 金额:$ 49.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-06-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:Adaptor Signaling ProteinAffinityAnti-DNA AntibodiesAntibodiesAntibody FormationAntibody ResponseAntigen ReceptorsAntigen-Antibody ComplexAntigensApoptoticAutoantibodiesAutoantigensAutoimmunityB-LymphocytesBenignCellsChromatinClinicalDNADeoxyribonucleasesDiseaseFlareGenomic DNAGlomerulonephritisHumanImmune responseImmune signalingImmunoglobulin GImmunologyInflammationLongitudinal StudiesMembraneModelingMusMutateMutationMyD88 proteinNatureNuclear AntigensNucleosomesPathogenicityPathologyPathway interactionsPatientsPhenotypeRegulationRibonucleoproteinsRoleSeveritiesSignal PathwaySignal TransductionSpecificitySpecimenSurfaceSystemic Lupus ErythematosusTestingTherapeuticTissuesTranslatingWorkautoreactivitybiobankcell typecirculating DNAds-DNAearly onsetexperienceextracellularimmune activationinnate immune mechanismsinsightnovelnovel strategiesresponsesensorserological markertool
项目摘要
ABSTRACT
The hallmark of systemic lupus erythematosus (SLE) is the production of antibodies to nuclear
antigens such as ribonucleoproteins and DNA, with the resulting immune complexes causing systemic
immune activation and tissue inflammation. High-affinity IgG antibodies to double-stranded DNA
(dsDNA) are particularly pathogenic and associate with the severity of tissue damage. The
mechanisms of tolerance to self-DNA and of its breakdown in SLE are poorly understood. We have
studied these mechanisms by focusing on DNASE1L3, a secreted DNase that is mutated in several
cases of early-onset familial SLE. We found that DNASE1L3-deficient mice develop a massive anti-
dsDNA antibody response, whereas the response to other antigens was absent or delayed. This
response and the ensuing immune activation and tissue damage required innate immune signaling
through the adaptor protein MyD88. DNASE1L3-deficient mice and human patients showed the
accumulation of genomic DNA within circulating apoptotic microparticles, and this DNA was
recognized by autoantibodies in a DNASE1L3-sensitive manner. Thus, DNASE1L3 maintains
tolerance to self-DNA by digesting potentially antigenic cell-extrinsic DNA in apoptotic microparticles.
The proposed work will apply the newly developed conceptual framework and experimental tools to
analyze the fundamental mechanisms of anti-DNA immune responses and their relevance to human
SLE. In Aim 1, we will use DNASE1L3-deficient mice as a model of primary anti-dsDNA reactivity to
characterize the nature and regulation of DNA-reactive B cells. In Aim 2, we will characterize innate
immune mechanisms of anti-DNA antibody response, particularly the identity of MyD88-dependent
sensing pathways. In Aim 3, we will translate our findings to human SLE patients, studying the
antibody response to DNASE1L3-sensitive chromatin on microparticles. Collectively, these studies
would provide insights into the origin and mechanisms of the pathogenic anti-DNA responses in SLE,
and facilitate targeted approaches towards their therapeutic blockade.
抽象的
系统性红斑狼疮(SLE)的标志是生产核的抗体
抗原,例如核糖核蛋白和DNA,产生的免疫复合物引起了全身性
免疫激活和组织炎症。对双链DNA的高亲和力IgG抗体
(DSDNA)特别致病,并与组织损伤的严重程度相关。这
对SLE的耐受性及其分解的耐受性的理解很少。我们有
研究了这些机制,通过专注于DNase1L3,这是一种分泌的DNase,在几种中被突变
早发性家族性SLE病例。我们发现DNase1l3缺陷型小鼠会形成大量的抗抗
dsDNA抗体反应,而对其他抗原的反应是不存在或延迟的。这
反应以及随之而来的免疫激活和组织损伤需要先天免疫信号
通过适配器蛋白MyD88。 DNASE1L3缺乏小鼠和人类患者显示
基因组DNA在循环凋亡微粒中的积累,该DNA为
由自身抗体以DNase1L3敏感的方式识别。因此,dnase1l3保持
通过在凋亡微粒中消化潜在的抗原细胞 - 超支DNA,对自动-DNA的耐受性。
拟议的工作将应用新开发的概念框架和实验工具
分析抗DNA免疫反应的基本机制及其与人的相关性
sle。在AIM 1中,我们将使用DNASE1L3缺陷型小鼠作为对原代抗DSDNA反应性的模型
表征DNA反应性B细胞的性质和调节。在AIM 2中,我们将以先天性来表征
抗DNA抗体反应的免疫机制,尤其是MyD88依赖性的身份
感知途径。在AIM 3中,我们将我们的发现转化为人类SLE患者,研究
对微粒上对DNase1L3敏感染色质的抗体反应。总的来说,这些研究
将提供有关SLE中致病性抗DNA反应的起源和机制的见解,
并促进针对其治疗性封锁的靶向方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jill P Buyon其他文献
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
索马鲁肽治疗 2 型糖尿病患者的心脏病研究
- DOI:
- 发表时间:
2019 - 期刊:
- 影响因子:0
- 作者:
Devyn Zaminski;Amit Saxena;P. Izmirly;Jill P Buyon;H. M. Belmont - 通讯作者:
H. M. Belmont
Jill P Buyon的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jill P Buyon', 18)}}的其他基金
Stopping Hydroxychloroquine In Elderly Lupus Disease (SHIELD)
停止使用羟氯喹治疗老年狼疮病 (SHIELD)
- 批准号:
10594743 - 财政年份:2023
- 资助金额:
$ 49.38万 - 项目类别:
HEALTH: Harnessing Epidemiology to Advance Lupus Treatment and Health
健康:利用流行病学促进狼疮治疗和健康
- 批准号:
10668437 - 财政年份:2022
- 资助金额:
$ 49.38万 - 项目类别:
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT) - Pain Supplement
狼疮组学皮肤肾脏调查小组 (LOCKIT) - 疼痛补充剂
- 批准号:
10861419 - 财政年份:2022
- 资助金额:
$ 49.38万 - 项目类别:
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)
狼疮组学皮肤肾研究小组 (LOCKIT)
- 批准号:
10452169 - 财政年份:2022
- 资助金额:
$ 49.38万 - 项目类别:
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)
狼疮组学皮肤肾研究小组 (LOCKIT)
- 批准号:
10596281 - 财政年份:2022
- 资助金额:
$ 49.38万 - 项目类别:
HEALTH: Harnessing Epidemiology to Advance Lupus Treatment and Health
健康:利用流行病学促进狼疮治疗和健康
- 批准号:
10552857 - 财政年份:2022
- 资助金额:
$ 49.38万 - 项目类别:
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
监测和治疗以预防胎儿房室传导阻滞可能很快发生(STOP BLOQ)
- 批准号:
10250529 - 财政年份:2020
- 资助金额:
$ 49.38万 - 项目类别:
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
监测和治疗以预防胎儿房室传导阻滞可能很快发生(STOP BLOQ)
- 批准号:
10440476 - 财政年份:2020
- 资助金额:
$ 49.38万 - 项目类别:
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
监测和治疗以预防胎儿房室传导阻滞可能很快发生(STOP BLOQ)
- 批准号:
10644022 - 财政年份:2020
- 资助金额:
$ 49.38万 - 项目类别:
Translational Center of Molecular Profiling in Preclinical and Established Lupus (COMPEL)
临床前和已确诊狼疮分子分析转化中心 (COMPEL)
- 批准号:
9766075 - 财政年份:2017
- 资助金额:
$ 49.38万 - 项目类别:
相似国自然基金
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于多尺度表征和跨模态语义匹配的药物-靶标结合亲和力预测方法研究
- 批准号:62302456
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
框架核酸多价人工抗体增强靶细胞亲和力用于耐药性肿瘤治疗
- 批准号:32301185
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Establishment of a Cell-Based Screening Platform for DNA Encoded Libraries
DNA编码文库细胞筛选平台的建立
- 批准号:
10646635 - 财政年份:2023
- 资助金额:
$ 49.38万 - 项目类别:
A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse events
揭示检查点抑制剂免疫相关不良事件基本机制的系统方法
- 批准号:
10637272 - 财政年份:2023
- 资助金额:
$ 49.38万 - 项目类别:
Structure-Function Studies of a Cell Penetrating Antibody that Inhibits DNA Repair
抑制 DNA 修复的细胞穿透抗体的结构功能研究
- 批准号:
10633740 - 财政年份:2023
- 资助金额:
$ 49.38万 - 项目类别: